Abstract
Small cell lung cancer (SCLC) is a devastating disease with rapid progression and limited treatment options (1). Topotecan is the only Food and Drug Administration (FDA) approved treatment option for recurrent or progressive SCLC, but has a median time to progression of less than four months (2). More effective therapies are urgently needed. Alkylating agents have shown single-agent efficacy in SCLC (3), and a recent phase II clinical trial demonstrated that temozolomide (TMZ), a non-classic oral alkylating agent, had activity in relapsed SCLC [overall response rate (ORR) 20%], particularly for brain metastasis (4). However, the median progression-free survival (PFS) time of TMZ was still only 3.5 months.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
